On October 6th, 2020 at 9:00 am Anja Trillhaase will defend her PhD thesis “Impact of the CAD risk locus 9p21 on vascular calcification – development of an iPSC-based model”.
We are looking forward to a great talk, vivid discussions, and an impressive Q&A session.
An editorial commentary on our article titled “Studies in zebrafish demonstrate that CNNM2 and NT5C2 are most likely the causal genes at the blood pressure-associated locus on human chromosome 10q24.32” has been reviewed and accepted for publication in Frontiers in Cardiovascular Medicine.
The title of this Editorial is “Of mice and men and zebrafishes. A promised land of discoveries for hypertension researchers” and states that, zebrafishes are going to be the tale for hypertension research in the immediate future.
We are grateful to the authors (Daniela Sorriento and Guido Iaccarino) for their very positive evaluation of our article.
The Editorial can be found here.
Happy to share that on September 23th 2020 from 15:30-15:45 Anja Trillhaase is going to present her work entitled “The influence of the 9p21 CAD risk locus on vascular calcification – an iPSC model” at the 8th Annual German Stem Cell Network (GSCN) Conference (Abstract T04 in session: Stem cells in disease modeling and drug development).
On Friday, September 4th, 2020 from 6:00 – 7:00 pm, Jeanette Erdmann and Thorsten Kessler (DHM, Munich) will talk about cardiovascular genetics at the “Cardiometabolism Virtual Seminar”. Please join us using Zoom ID 692-600-595.
Jeanette Erdmann, Cardiovascular genetics: Past, Present, Future
Thorsten Kessler, Insights from the GUCY1A1 coronary artery disease locus
The ICG is happy to announce, that Jeanette Erdmann and Franziska Haarich are amongst the recipients of Cure CMD´s 2020 Grant Awards. According to the CureCMD press release “Grants have been awarded in five subtypes: Dystroglycanopathy, Collagen VI, LAMA2, LMNA, and SELENON (SEPN1). The projects range from a study in mouse models, to new projects in gene therapy, to an extended grant focused on genetic modifiers.”
“The process was extremely competitive this year,” says Cure CMD’s Scientific Director, Dr. Gustavo Dziewczapolski. “In previous cycles we have had perhaps a dozen applicants. This year, we received a record-breaking 30 applications, which is thrilling because it indicates an expanded interest in CMD research — something we at Cure CMD have continued to cultivate over the last decade.”
The study by J. Erdmann and F. Haarich entitled: First steps towards an RNA-based therapy for COL6-MD using CRISPR interference will evaluate the unique characteristics of the gene copy (allele) carrying some of the more common Collagen VI dominant mutations, in order to target and inhibit the mutant allele and spare the unaffected allele. The team will evaluate a novel treatment strategy, called CRISPR interference (CRISPRi), to achieve suppression of the faulty gene. CRISPRi is a type of CRISPR technology, which may be safer by acting on RNA rather than directly on DNA.